Enoxaparin treatment dosing for venous thromboembolism in pediatric patients with obesity.

Juwon YimAfrin JahanNikolay BraykovGary M Woods

Published in: Pediatric blood & cancer (2024)

Pediatric patients with obesity required a lower weight-based dose of enoxaparin to achieve a therapeutic anti-Xa than the recommended starting dose of 1 mg/kg twice daily for treatment of VTE. Among obesity indices, weight showed the strongest negative correlation with total daily enoxaparin requirement.

Keyphrases

venous thromboembolism
weight loss
weight gain
insulin resistance
metabolic syndrome
direct oral anticoagulants
physical activity
type diabetes
high fat diet induced
body mass index
combination therapy
young adults